Evidence map›Paper›PMID 42112229›Full record

ArticleInfection and drug resistance2026

Molecular Epidemiology of Carbapenem-Resistant

Wei Hong, Chunli Yang, Xiaoyu Zhao, Wen Wang, Liang Wang, Changmei Gu, Wei Jia, Jia Tao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical and Microbiological Profile ofInfection and drug resistance · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei Hong *Center of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Chunli Yang *The First Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Xiaoyu ZhaoCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Wen WangCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Liang WangCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Changmei GuCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Wei JiaCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.
Jia TaoCenter of Medical Laboratory, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Carbapenem-resistant Patients and Methods: Twelve non-duplicate clinical CRSM isolates were collected from a tertiary hospital between 2010 and 2024. Clinical data were retrospectively obtained from electronic medical records. Antimicrobial susceptibility testing was performed using the Vitek-2 system. Whole-genome sequencing (WGS) was conducted to determine resistance and virulence gene profiles, sequence types, and phylogenetic relationships. Pulsed-field gel electrophoresis and conjugation assays were performed to assess clonal relatedness and plasmid transferability. Results: CRSM infections predominantly occurred in neonates (50.0%) and adults (50.0%), with the respiratory tract as the most common infection site (66.7%). All isolates exhibited multidrug-resistant phenotypes; resistance to β-lactams ranged from 50.0% to 100.0%, while no amikacin-resistant isolates were detected. Two dominant clonal lineages were identified: ST595 (5 strains) uniformly carrying Conclusion: CRSM dissemination in this hospital is likely driven by two co-circulating high-risk clones (ST595-

Indexed as

carbapenem-resistantMLSTSerratia marcescenswhole-genome sequencing

Identifiers

PMID42112229
PMCPMC13156979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.